Business Context and Reporting Period
This Form 8-K filing by Daxor Corporation reports a significant corporate governance event dated September 22, 2016. The report details the outcome of a Board of Directors meeting held on September 21, 2016, concerning the appointment of new executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused solely on personnel changes and does not contain financial performance data.
Material Changes
- Executive Appointment: Michael Feldschuh (age 47) was unanimously appointed as the permanent President and Chief Executive Officer. He had previously served in an acting capacity since December 2015.
- Executive Departure: Dr. Joseph Feldschuh voluntarily stepped down as President and Chief Executive Officer due to ongoing medical issues.
- Role Transition: Dr. Feldschuh will retain his positions as Chairman of the Board and Chief Financial Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, future outlook, or discussion of material risks and contingencies. The primary focus is the transition of executive duties to ensure continuity of leadership.
Investor Verification Checklist
- Verify the effective date of Michael Feldschuh's permanent appointment as CEO.
- Confirm Dr. Joseph Feldschuh's continued tenure as Chairman and CFO.
- Review subsequent filings for any impact of the leadership transition on strategic direction or financial performance.